Related Experiment Video
Updated: Sep 16, 2025
08:15
Gastrointestinal Motility Monitor GIMM
Published on: December 1, 2010
31.0K
Gastrointestinal Motility Effects of GLP-1 Receptor Agonists
Danielle Bellavance1, Samantha Chua2, Hiroshi Mashimo3
1Department of Medicine, VA Boston Healthcare System, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
Current Gastroenterology Reports
|July 7, 2025
Summary
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) significantly impact gastrointestinal motility, influencing their therapeutic benefits and common side effects like nausea and delayed gastric emptying.
Area of Science:
- Gastroenterology
- Endocrinology
- Pharmacology
Background:
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective for diabetes and obesity.
- GLP-1 RAs mimic the natural hormone GLP-1, impacting glucose metabolism and weight.
- Gastrointestinal (GI) motility alterations are a key mechanism for GLP-1 RA metabolic effects.
Purpose of the Study:
- To review the physiological effects of GLP-1 RAs on GI motility.
- To highlight clinical implications of these motility changes.
- To identify future research directions.
Main Methods:
- Literature review of current understanding.
- Analysis of physiological mechanisms.
- Synthesis of clinical evidence.
Main Results:
- GLP-1 RAs affect motility throughout the GI tract.
- Delayed gastric emptying is a well-documented effect.
- Altered motility contributes to adverse effects like nausea, vomiting, and early satiety.
Conclusions:
- GLP-1 RA-induced GI motility changes are central to their action and tolerability.
- Clinical implications include aspiration risk and adherence challenges.
- Further research is needed to fully understand and manage these effects.
Related Concept Videos
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
629
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
629
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
412
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
412
01:24Glucagon-like Receptor Agonists
431
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
431
01:22Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
307
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
307
01:20Gastrointestinal Motility Disorders
609
Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
609
01:20Drugs Affecting GI Tract Motility: Other Laxatives
471
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
471